Hologic Inc

Most Recent

  • uploads///HOLX
    Company & Industry Overviews

    How Hologic Stock Has Fared in the Last Month

    After rising from $36.53 on April 9, 2018, to $42.91 on July 31, 2018, Hologic (HOLX) stock slid to $37.90 on October 29, 2018.

    By Kenneth Smith
  • uploads///HOLX
    Company & Industry Overviews

    What Analysts Recommend for Hologic Stock

    In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///hospital _
    Company & Industry Overviews

    How Hologic’s Revenue Is Trending

    For fiscal 2019 and 2020, Hologic (HOLX) is expected to generate total revenues of $3.32 billion and $3.45 billion, respectively.

    By Kenneth Smith
  • uploads///hologic recommendations
    Company & Industry Overviews

    Cynosure Headwinds Trigger Analyst Downgrades on HOLX Stock

    As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.

    By Sarah Collins
  • uploads///guidance
    Company & Industry Overviews

    Hologic’s Cynosure Headwinds Could Impact 2018 Earnings

    On September 12, Hologic (HOLX) provided an update on the financial impact of the suspension of its marketing and distribution of the company’s Vitalia handpieces and probes.

    By Sarah Collins
  • uploads///hospital _
    Company & Industry Overviews

    A Look at Hologic Stock’s Recent Performance

    Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    How Hologic’s Valuation Stacks Up with Peers

    The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Hologic Stock Down ~9% Year-to-Date

    On September 6, Hologic (HOLX) ended the day at $38.74.

    By Sarah Collins
  • uploads///TFX
    Company & Industry Overviews

    Analysts Still Bullish on Teleflex Stock

    Teleflex’s (TFX) interest expenses increased from $19.89 million in the second quarter of 2017 to $26.65 million in the second quarter of 2018.

    By Kenneth Smith
  • uploads///Diagnostics segment
    Healthcare

    How Is Roche’s Diagnostics Segments Positioned in August?

    Roche’s tissue diagnostics unit generated revenues of 290.0 million Swiss francs in the second quarter, reflecting ~15% YoY growth at CER.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Hologic’s GYN Surgical Business Grew in Fiscal Q3 2018

    In the fiscal third quarter, NovaSure witnessed a YoY revenue decline of 7.6%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Diagnostics Business Emerges as a Key Growth Driver in Fiscal Q3

    In fiscal Q3 2018, Hologic (HOLX) reported revenues of ~$294.3 million for its Diagnostics segment.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at Hologic’s Acquisition of Faxitron Bioptics

    In the fiscal third quarter, Hologic reported revenues of ~$307.9 million for its biggest business, Breast Health.

    By Margaret Patrick
  • uploads///mammography _
    Company & Industry Overviews

    Analysts’ Recommendations for Hologic and Its Peers in August

    Of the 19 analysts covering Hologic (HOLX) in August, five rated it as a “strong buy,” and seven rated it as a “buy.”

    By Margaret Patrick
  • uploads///sales estimates
    Earnings Report

    What to Expect from Hologic’s Fiscal Third-Quarter Results

    In the third quarter of 2018, Wall Street analysts estimate Hologic will register adjusted EPS of $0.56, a YoY increase of ~11.9%.

    By Sarah Collins
  • uploads///ken treloar  unsplash
    Earnings Report

    Hologic Stock Falls Over 9% on 2Q18 Results, Lower 2018 Guidance

    Yesterday, after the market closed, Hologic (HOLX) released its 2Q18 earnings results for the quarter that ended on March 31.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Can HOLX Stock Rebound from Its Recent Lows?

    On March 28, 2018, Hologic (HOLX) stock ended trading at a closing price of $37.39.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Wall Street Largely Bullish on Hologic Stock in March

    Of the 20 brokerage firms covering HOLX stock, 75% of them have a “buy” or “strong buy” recommendation for the stock.

    By Sarah Collins
  • uploads///rd pipeline
    Company & Industry Overviews

    Hologic and Dexalytics Partner to Develop Software for Athletes

    On February 22, 2018, Hologic (HOLX) announced it has entered into an agreement with the University of Minnesota as the exclusive provider of Dexalytics: Teams.

    By Sarah Collins
  • uploads///BREAST HEALTH BUSINESS PERFORMANCE
    Company & Industry Overviews

    Philips and Hologic Partners in Women’s Health Area

    On March 2, 2018, Hologic (HOLX) announced a global partnership with Royal Philips (PHG) to provide an integrated health solution for women.

    By Sarah Collins
  • uploads///october pink _
    Company & Industry Overviews

    Hologic Gets FDA Approval for Its New 3D Imaging Technology

    On March 27, Hologic (HOLX) announced that the FDA has approved its Clarity HD high-resolution 3D imaging and Intelligent 2D imaging.

    By Sarah Collins
  • uploads///q_sales
    Company & Industry Overviews

    Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’

    On January 9, 2018, Mizuho Securities upgraded Teva Pharmaceutical Industries (TEVA) from a “neutral” to a “buy” rating. It came after Teva announced its business restructuring plan.

    By Sarah Collins
  • uploads///Grph
    Company & Industry Overviews

    Can Edwards Lifesciences See Robust Net Profit Margin in 2017?

    In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Abiomed’s Profit Margin Expectations for Fiscal 2018

    For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Baxter Expected to Report Robust Revenue Growth in 2017

    Baxter International (BAX) has projected its YoY (year-over-year) revenue growth for 2017 at 1.0%–2.0% on a reported basis.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Does Novartis See Much Potential for Its Surgical Business?

    In 2017, Novartis (NVS) has planned to conduct a review of its Alcon segment to evaluate the business’s growth potential.

    By Margaret Patrick
  • uploads///phg pm
    Company & Industry Overviews

    Philips Introduces New Imaging and Treatment Planning Solutions

    Koninklijke Philips (PHG) has a market cap of $28.0 billion. It fell 1.1% to close at $29.44 per share on September 26.

    By Gabriel Kane
  • uploads///phg pm
    Company & Industry Overviews

    Philips Acquires PathXL to Expand Its Business

    Koninklijke Philips (PHG) has a market cap of $24.5 billion. It rose by 1.8% and closed at $26.15 per share on June 21, 2016.

    By Gabriel Kane
  • uploads///Part  Graph
    Company & Industry Overviews

    How Are IHI’s Holdings’ Moving Averages Trending?

    IHI has 47 stocks in its portfolio. As of June 9, 2016, 94% of IHI’s stocks were trading above their 20-day moving averages.

    By Peter Neil
  • uploads///phg pm
    Company & Industry Overviews

    Philips Announced the Pricing of Its Lighting IPO

    Koninklijke Philips (PHG) raised 750 million euros ($839 million) from its initial public offering (or IPO) of its Lighting business.

    By Gabriel Kane
  • uploads///phg pm
    Company & Industry Overviews

    Exane BNP Paribas Upgrades Koninklijke Philips to ‘Outperform’

    Koninklijke Philips (PHG) has a market cap of $24.7 billion. It fell by 0.94% to close at $26.48 per share on May 11, 2016.

    By Gabriel Kane
  • uploads///phg pm
    Earnings Report

    Koninklijke Philips Reported Mixed Quarterly Results for 1Q16

    Koninklijke Philips (PHG) has a market cap of $25.4 billion. PHG fell by 4.2% to close at $27.09 per share on April 25, 2016.

    By Gabriel Kane
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Boston Scientific Led IHI’s Large Caps

    Boston Scientific (BSX) rose 1.5% as of November 6, 2015. The stock closed at $18.94 and was trading above its 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///ayi cr
    Earnings Report

    How Does Acuity Brands Compare to Its Peers?

    Acuity Brands is way ahead of its competitors based on gross profit margin, EPS, and current, PE, and PBV ratios.

    By Gabriel Kane
  • uploads///gks coo
    Earnings Report

    Cooper Companies Reported Mixed 2Q15 Results

    Cooper Companies (COO) is a $7.33 billion global medical device company. The company has two business units, CooperVision and CooperSurgical.

    By Gabriel Kane
  • uploads///US High Yield Bond Fund Flows
    Company & Industry Overviews

    Outflows Continue in High-Yield Bond Funds: Week to June 19

    Last week, investor flows in high-yield bond funds remained in negative territory for the second week in a row. They’ve witnessed inflows of $2.6 billion YTD.

    By David Ashworth
  • uploads///Relational positions
    Fund Managers

    Assessing Relational Investors’ holdings in fourth quarter

    This article discusses Relational Investors’ holdings for the fourth quarter of 2014.

    By Samantha Nielson
  • uploads///Apple Cash Balance Position
    Healthcare

    Apple expands its capital return program: Is the stock undervalued?

    Apple announced an increase in the size of its capital return program by an addition of $30 billion for a total program size of over $130 billion.

    By Puneet Sikka
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.